Envestnet Asset Management Inc. Has $27.41 Million Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Envestnet Asset Management Inc. cut its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 5.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,356,786 shares of the company’s stock after selling 75,687 shares during the period. Envestnet Asset Management Inc. owned 0.12% of Teva Pharmaceutical Industries worth $27,407,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Advisors Asset Management Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the 2nd quarter worth approximately $41,000. Cromwell Holdings LLC boosted its stake in Teva Pharmaceutical Industries by 40.3% in the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after purchasing an additional 629 shares in the last quarter. MAI Capital Management boosted its stake in Teva Pharmaceutical Industries by 26.8% in the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock worth $55,000 after purchasing an additional 697 shares in the last quarter. LRI Investments LLC grew its holdings in shares of Teva Pharmaceutical Industries by 246.0% during the third quarter. LRI Investments LLC now owns 2,813 shares of the company’s stock worth $57,000 after purchasing an additional 2,000 shares during the last quarter. Finally, JTC Employer Solutions Trustee Ltd acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at $65,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA opened at $33.92 on Friday. The stock has a 50 day simple moving average of $31.97 and a 200 day simple moving average of $24.31. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $37.35. The firm has a market capitalization of $38.90 billion, a PE ratio of 28.27, a P/E/G ratio of 1.95 and a beta of 0.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The business had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. During the same period in the previous year, the firm posted $0.71 EPS. The firm’s revenue was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Sell-side analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on TEVA shares. The Goldman Sachs Group upped their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Barclays raised their price target on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a report on Friday, January 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, January 21st. Finally, Scotiabank increased their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $37.11.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, CAO Amir Weiss sold 12,300 shares of the company’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total transaction of $371,460.00. Following the sale, the chief accounting officer owned 5,650 shares in the company, valued at approximately $170,630. This represents a 68.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Richard Daniell sold 115,468 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total value of $3,311,622.24. Following the transaction, the vice president directly owned 48,384 shares in the company, valued at $1,387,653.12. This trade represents a 70.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 422,060 shares of company stock valued at $12,254,965 over the last ninety days. 0.49% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.